Similar articles

• Effects of colestipol-niacin therapy on human femoral atherosclerosis.

  Blankenhorn DH, Azen SP, Crawford DW, Nessim SA, Sanmarco ME, Selzer RH, Shircore AM, Wickham EC. Blankenhorn DH, et al. Circulation. 1991 Feb;83(2):438-47. doi: 10.1161/01.cir.83.2.438. Circulation. 1991. PMID: 1991366 Clinical Trial.
• The Cholesterol Lowering Atherosclerosis Study (CLAS): design, methods, and baseline results.

  Blankenhorn DH, Johnson RL, Nessim SA, Azen SP, Sanmarco ME, Selzer RH. Blankenhorn DH, et al. Control Clin Trials. 1987 Dec;8(4):356-87. doi: 10.1016/0197-2456(87)90156-5. Control Clin Trials. 1987. PMID: 3327654 Clinical Trial.
• The Cholesterol Lowering Atherosclerosis Study (CLAS): what it tells us about niacin/colestipol therapy.

  Hemphill LC. Hemphill LC. J Clin Lipidol. 2015 Jan-Feb;9(1):11-3. doi: 10.1016/j.jacl.2014.09.010. Epub 2014 Sep 30. J Clin Lipidol. 2015. PMID: 25670355 No abstract available.
• When to treat hyperlipidemia.

  Kane JP, Malloy MJ. Kane JP, et al. Adv Intern Med. 1988;33:143-63. Adv Intern Med. 1988. PMID: 3278503 Review. No abstract available.
• Dietary fat and atherosclerosis.

  Glueck CJ. Glueck CJ. Am J Clin Nutr. 1979 Dec;32(12 Suppl):2703-11. doi: 10.1093/ajcn/32.12.2703. Am J Clin Nutr. 1979. PMID: 389025 Review. No abstract available.